Eli Lilly (NYSE: LLY) has emerged as one of the hottest stocks in the GLP-1 realm -- underscored by its combination of ...

Weight loss is a key effect of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), but these drugs may also provide liver ...

Glucagon-like peptide-1 agonists, a class of medications known as GLP-1s, have grown in popularity, initially for the treatment of type 2 diabetes ...

Glucagon-like peptide-1 (GLP-1) receptor agonists are peptide-based therapeutics for treating diabetes and for weight loss., ...

Novo Nordisk’s attempt to create a successor to its weight loss blockbuster Wegovy may have taken a hit with recent ...

Patients with diabetes or obesity receiving GLP-1 RAs are unlikely to experience an increase in the already low rates of ...

HealthDay News — Preoperative glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is not associated with short-term postoperative aspiration pneumonia, according to a study published online March ...

Investigating GLP-1 RAs reveals their impact on women's health, addressing metabolic disorders, reproductive health, and ...

The following is a summary of “Hematologic Cancers Among Patients With Type 2 Diabetes Prescribed GLP-1 Receptor Agonists,” ...

GLP-1 RA use was associated with significantly lower risk of certain cancers compared with metformin use and insulin use.

Employers, including Express Scripts parent company Cigna, seek to manage GLP-1 costs through programs administered by the ...

Glucagon-like peptide-1 (GLP-1) receptor agonists are peptide-based therapeutics for treating diabetes and for weight loss.